Based on the power of attorney granted at the annual general meetings of NattoPharma ASA ("NattoPharma" or "Company") on June 25, 2015 and May 20, 2016, the Board of Directors of NattoPharma has in board proceedings June 24th, 2016 approved a share issue of 305 000 new shares, each with a face value of NOK 3 per share. 

The share issue will be completed through issuance of new shares to leading employees in accordance with the company’s incentive program according to the following plan;

Name  Position / Function  Granted shares  Shares prior to share issue  Shares after share issue 
Daniel H. Rosenbaum  CEO                  100.000   0                  100.000  
Kjetil Ramsøy  CFO                  100.000   0                  100.000  
Eric Anderson  VP Sales & Marketing                    50.000   0                    50.000  
Rudi de Man  VP Sales Europe & Asia                    30.000   0                    30.000  
William Sommer VP Global Development and Regulatory                    25.000   0                    25.000  

Price to be paid for each share is NOK 3 per share. The share issue is expected to be completed within July 31st, 2016.

As a result, the share capital will be increased by NOK 915 000. The Company’s new share capital after the share issue will be NOK 52 334 799 divided into 17 444 933 shares, each with a face value of NOK 3.

* * *

For more information, please contact:

Kjetil Ramsøy, Chief Financial Officer


This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.


Documents & Links